2,027 reports of this reaction
1.9% of all PIMAVANSERIN TARTRATE reports
#11 most reported adverse reaction
GAIT DISTURBANCE is the #11 most commonly reported adverse reaction for PIMAVANSERIN TARTRATE, manufactured by Acadia Pharmaceuticals Inc.. There are 2,027 FDA adverse event reports linking PIMAVANSERIN TARTRATE to GAIT DISTURBANCE. This represents approximately 1.9% of all 106,130 adverse event reports for this drug.
PIMAVANSERIN TARTRATE has an overall safety score of 85 out of 100. Patients taking PIMAVANSERIN TARTRATE who experience gait disturbance should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
GAIT DISTURBANCE is a less commonly reported adverse event for PIMAVANSERIN TARTRATE, but still significant enough to appear in the safety profile.
In addition to gait disturbance, the following adverse reactions have been reported for PIMAVANSERIN TARTRATE:
The following drugs have also been linked to gait disturbance in FDA adverse event reports:
GAIT DISTURBANCE has been reported as an adverse event in 2,027 FDA reports for PIMAVANSERIN TARTRATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
GAIT DISTURBANCE accounts for approximately 1.9% of all adverse event reports for PIMAVANSERIN TARTRATE, making it a notable side effect.
If you experience gait disturbance while taking PIMAVANSERIN TARTRATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.